IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 290, 397, 399, 425, 426 & 468**

SECOND NOTICE OF PREVIOUSLY OMITTED CONTRACTS DESIGNATED AS ASSIGNED CONTRACTS IN CONNECTION WITH FABRY SALE TRANSACTION

PLEASE TAKE NOTICE OF THE FOLLOWING

On September 2, 2026, the United States Bankruptcy Court for the District of Delaware (the "**Court**") entered the *Order (A) Authorizing the Sale of the Debtor's Assets Free and Clear of All Liens, Claims, Interests, and Encumbrances; (B) Approving Assumption and Assignment of the Assigned Contracts; and (C) Granting Related Relief* [Docket No. 426] (the "**Fabry Sale Order**").[2] The Fabry Sale Order, among other things: (i) authorized Sangamo Therapeutics, Inc., the above-captioned debtor and debtor-in-possession (the "**Debtor**"), to enter into that certain *Asset Purchase Agreement* (the "**Fabry Purchase Agreement**") pursuant to which the Debtor agreed to sell (the "**Fabry Sale Transaction**") the assets described in the Fabry Purchase Agreement to PTC Therapeutics, Inc. ("**PTC**"), (ii) authorized and approved the assumption and assignment of certain executory contracts (the "**Assigned Contracts**") in connection with the Fabry Sale Transaction, and (iii) authorized the Debtor to take all actions necessary to consummate the Fabry Sale Transaction. The Fabry Sale Transaction closed on September 17, 2026 (the "**Closing Date**").

Pursuant to paragraphs 34 and 35 of the Fabry Sale Order, PTC designated certain Previously Omitted Contracts to be Assigned Contracts (the "**Designated Assigned Contracts**"). Attached hereto as **Exhibit A** is a list of the Designated Assigned Contracts to be assumed and assigned to PTC in connection with the Fabry Sale Transaction, together with the Debtor's calculation of Cure Costs (if any) with respect to such Designated Assigned Contracts. The inclusion of any Designated Assigned Contracts on **Exhibit A** does not: (i) constitute an admission by the Debtor, PTC, or any other party that such Designated Assigned Contracts are executory contracts or unexpired leases within the meaning of the Bankruptcy Code or (ii) require or guarantee that such Designated Assigned Contracts ultimately will be assumed or assigned. All rights of the Debtor with respect thereto are reserved.

[1] The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 7000 Marina Blvd, Brisbane, CA 94005.

[2] Capitalized terms used but not defined herein have the meanings given to them in the Fabry Sale Order.

2610989261022000000000004

In addition, to the extent that any of the Cure Costs (if any) set forth on **Exhibit A** do not reflect (i) postpetition payments that have been made by the Debtor with respect to applicable Cure Costs (if any) or (ii) any payments that are made by the Debtor with respect to such Cure Costs (if any) after the filing of this notice, the respective amounts required to be paid to cure any existing defaults under the applicable Designated Assigned Contracts shall be reduced by any such corresponding postpetition payments, and the Debtor reserves its rights to update the Cure Costs (if any) set forth on **Exhibit A** accordingly, either by filing a supplemental notice with the Court or by written notice to the applicable counterparty.

Pursuant to paragraphs 34 and 35 of the Fabry Sale Order, any counterparty to a Designated Assigned Contract that wishes to object to the assumption and assignment of such Designated Assigned Contract to PTC (including, without limitation, PTC's proposed form of adequate assurance of future performance and the associated Cure Costs (if any) with respect to such Designated Assigned Contract (each such objection, an "**Adequate Assurance/Cure Objection**")) must file its Adequate Assurance/Cure Objection with the Court by no later than **November 5, 2026, at 4:00 p.m. (Eastern Time**), which must be in writing and state, with specificity, the legal and factual bases thereof, the amount the counterparty believes to be the correct Cure Cost if objecting to any associated Cure Cost, and include any appropriate documentation in support thereof.

IF A COUNTERPARTY TO A DESIGNATED ASSIGNED CONTRACT FAILS TO FILE WITH THE COURT A TIMELY ADEQUATE ASSURANCE/CURE OBJECTION, THEN THE COUNTERPARTY: (A) SHALL BE FOREVER BARRED, ESTOPPED AND ENJOINED FROM ASSERTING (1) ANY OBJECTION TO THE ASSUMPTION AND/OR ASSIGNMENT, (2) ANY OBJECTION WITH REGARD TO THE COST TO CURE ANY DEFAULTS UNDER THE APPLICABLE DESIGNATED ASSIGNED CONTRACT, AND (3) THAT ANY CONDITIONS TO THE ASSUMPTION AND ASSIGNMENT OF SUCH DESIGNATED ASSIGNED CONTRACT HAVE NOT BEEN SATISFIED PURSUANT TO SECTION 365(b)(1) OF THE BANKRUPTCY CODE OR OTHERWISE; (B) THE CURE COSTS SET FORTH ON EXHIBIT A HERETO SHALL BE CONTROLLING AND WILL BE THE ONLY AMOUNT NECESSARY TO CURE OUTSTANDING DEFAULTS UNDER THE DESIGNATED ASSIGNED CONTRACT AND SATISFY THE REQUIREMENTS OF SECTION 365(b) OF THE BANKRUPTCY CODE, AND THE COUNTERPARTY TO THE DESIGNATED ASSIGNED CONTRACT SHALL BE DEEMED BOUND BY AND TO HAVE CONSENTED TO THE CURE AMOUNTS; AND (C) PTC SHALL BE DEEMED TO HAVE PROVIDED ADEQUATE ASSURANCE OF FUTURE PERFORMANCE WITH RESPECT TO THE DESIGNATED ASSIGNED CONTRACTS IN ACCORDANCE WITH BANKRUPTCY CODE SECTIONS 365(b)(1)(C), 365(f)(2)(B) AND, IF APPLICABLE, 365(b)(3), NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE DESIGNATED ASSIGNED CONTRACT.

Dated: October 22, 2026
Wilmington, Delaware

/s/ James F. McCauley

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
James F. McCauley (No. 6991)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
mccauley@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession

Exhibit A

Designated Assigned Contracts

Contract Counterparty	Contract Description	Cure Amount[1]
Frontage Laboratories, Inc.	Master Laboratory Services Agreement	$154.98
Frontage Laboratories, Inc.	Work Order under the Master Laboratory Services Agreement	$0.00
Frontage Laboratories, Inc.	Work Order under the Master Laboratory Services Agreement	$0.00
Frontage Laboratories, Inc.	Change Order #1 to Work Order under the Master Laboratory Services Agreement	$0.00
Regents of the University of Minnesota	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Regents of the University of Minnesota	Amendment #1 Clinical Trial Agreement	$0.00
Regents of the University of Minnesota	Amendment #2 Clinical Trial Agreement	$0.00
Regents of the University of Minnesota	Amendment #3 Clinical Trial Agreement	$0.00
Regents of the University of Minnesota	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Regents of the University of Minnesota	Amendment #1 Clinical Study Agreement (Long-Term Follow-up)	$0.00
University of Pittsburgh	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
University of Pittsburgh	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00

[1] The Cure Amounts set forth herein do not reflect postpetition payments that have been made by the Debtor. Postpetition amounts arising under the Designated Assigned Contracts will be paid in the ordinary course and not in connection with payments made to satisfy the Cure Amounts.

Contract Counterparty	**Contract Description**	**Cure Amount**[1]
University of Pittsburgh	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cincinnati Children's Hospital Medical Center	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cincinnati Children's Hospital Medical Center	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cincinnati Children's Hospital Medical Center	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cincinnati Children's Hospital Medical Center	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Cincinnati Children's Hospital Medical Center	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
New York University School of Medicine	Clinical Trial Agreement (Protocol ST-920-201)	$0.00
Emory University	Clinical Trial Agreement (Protocol ST-920-201)	$0.00
Emory University	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-201)	$0.00
Emory University	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-201)	$0.00
Emory University	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Emory University	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The University of South Florida Board of Trustees	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The University of South Florida Board of Trustees	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00

Contract Counterparty	Contract Description	Cure Amount[1]
The University of South Florida Board of Trustees	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital	Facility Use Agreement (related to Protocol ST-920-01 Clinical Trial Agreement with The University of South Florida Board of Trustees)	$0.00
The University of South Florida Board of Trustees	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The University of South Florida Board of Trustees	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Vanderbilt University Medical Center	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Vanderbilt University Medical Center	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Ann & Robert H. Lurie Children's Hospital of Chicago	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Ann & Robert H. Lurie Children's Hospital of Chicago	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Ann & Robert H. Lurie Children's Hospital of Chicago	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The University of Florida Board of Trustees	Clinical Trial Agreement (Protocol ST-920-201)	$0.00
The University of Iowa	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The University of Iowa	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The University of Iowa	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The University of Iowa	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00

Contract Counterparty	Contract Description	Cure Amount[1]
The University of Iowa	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The University of Iowa	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The University of Iowa	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #4 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Lysosomal & Rare Disorders Research & Treatment Center, Inc.	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Icahn School of Medicine at Mount Sinai	Clinical Trial Agreement (Protocol ST-920-01)	$0.00

Contract Counterparty	Contract Description	Cure Amount[1]
Icahn School of Medicine at Mount Sinai	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Icahn School of Medicine at Mount Sinai	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Icahn School of Medicine at Mount Sinai	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Icahn School of Medicine at Mount Sinai	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Icahn School of Medicine at Mount Sinai	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Icahn School of Medicine at Mount Sinai	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Icahn School of Medicine at Mount Sinai	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The Regents of the University of California, on behalf of its Irvine Campus	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The Regents of the University of California, on behalf of its Irvine Campus	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The Regents of the University of California, on behalf of its Irvine Campus	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
The Regents of the University of California, on behalf of its Irvine Campus	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
The Regents of the University of California, on behalf of its Irvine Campus	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00

Contract Counterparty	Contract Description	Cure Amount[1]
The Regents of the University of California, on behalf of its Irvine Campus	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
M.A.G.I.C. Clinic LTD	Clinical Trial Agreement (Protocol ST-920-201)	$0.00
M.A.G.I.C. Clinic LTD	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-201)	$0.00
M.A.G.I.C. Clinic LTD	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-201)	$0.00
M.A.G.I.C. Clinic LTD	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
M.A.G.I.C. Clinic LTD	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Royal Free London NHS Foundation Trust	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Royal Free London NHS Foundation Trust	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Royal Free London NHS Foundation Trust	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Royal Free London NHS Foundation Trust	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Royal Free London NHS Foundation Trust	Amendment #4 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Royal Free London NHS Foundation Trust	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00

Contract Counterparty	Contract Description	Cure Amount[1]
Cambridge University Hospitals NHS Foundation Trust	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Amendment #3 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Amendment #4 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Cambridge University Hospitals NHS Foundation Trust	Amendment #2 to Clinical Trial Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
University Hospitals Birmingham NHS Foundation Trust	Clinical Trial Agreement (Protocol ST-920-01)	$0.00
University Hospitals Birmingham NHS Foundation Trust	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-01)	$0.00
Azienda Ospedaliero-Universitaria Careggi	Clinical Investigation Agreement (Protocol ST-920-01)	$0.00
Azienda Ospedaliero-Universitaria Careggi	Amendment #1 to Clinical Investigation Agreement (Protocol ST-920-01)	$0.00
Azienda Ospedaliero-Universitaria Careggi	Amendment #2 to Clinical Investigation Agreement (Protocol ST-920-01)	$0.00
Universitatsklinikum Wurzburg	Clinical Study Agreement (Protocol ST-920-201)	$0.00
Universitätsklinikum Würzburg	Amendment #1 to Clinical Study Agreement (Protocol ST-920-201)	$0.00
Universitatsklinikum Wurzburg	Clinical Study Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00

Contract Counterparty	**Contract Description**	**Cure Amount**[1]
Universitätsklinikum Würzburg	Amendment #1 to Clinical Study Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Universitatsklinikum Hamburg-Eppendorf	Clinical Trial Agreement (Protocol ST-920-201)	$0.00
Universitätsklinikum Hamburg-Eppendorf	Amendment #1 to Clinical Trial Agreement (Protocol ST-920-201)	$0.00
National Taiwan University Hospital	Clinical Study Agreement (Protocol ST-920-201)	$0.00
National Taiwan University Hospital	Amendment #1 to Clinical Study Agreement (Protocol ST-920-201)	$0.00
Melbourne Health (The Royal Melbourne Hospital)	Clinical Trial Research Agreement (Protocol ST-920-201)	$0.00
Melbourne Health (The Royal Melbourne Hospital)	Amendment #1 to Clinical Trial Research Agreement (Protocol ST-920-201)	$0.00
Melbourne Health (The Royal Melbourne Hospital)	Amendment #2 to Clinical Trial Research Agreement (Protocol ST-920-201)	$0.00
Melbourne Health (The Royal Melbourne Hospital)	Clinical Trial Research Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00
Melbourne Health (The Royal Melbourne Hospital)	Amendment #1 to Clinical Trial Research Agreement (Protocol ST-920-LT01 – Long-Term Follow-up)	$0.00